17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they would collaborate on developing a ...

In the 14-week phase 2b study by Sanofi and Teva's U.S. affiliate held in the U.S., Europe and Israel, the drug, called duvakitug, showed that 36.2% of low dose and 47.8% of high dose patients ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...

Merck is working on the monoclonal antibody MK-7240—formerly known as PRA023—which it acquired in its $10.8 billion buyout of Prometheus Biosciences last year. In phase 2 results disclosed in ...

ADRs of Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) traded higher in the premarket on Tuesday after the companies said that their experimental antibody therapy, duvakitug, reached the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

A Teva Pharmaceuticals drug being developed in partnership with Sanofi to hit a promising but competitive target for inflammation now has positive data from a clinical test in the two most common ...